Search results for "PLACEBO"

showing 10 items of 704 documents

Local anaesthetic sympathetic blockade for complex regional pain syndrome

2016

This is the peer reviewed version of the following article: The Cochrane database of systematic reviews, which has been published in final form at https://doi.org/10.1002/14651858.CD004598.pub4. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving. Background: This review is an update of a previously published review in the Cochrane Database of Systematic Reviews, 2005, Issue 4 (and last updated in the Cochrane Database of Systematic Reviews, 2013 issue 8), on local anaesthetic blockade (LASB) of the sympathetic chain to treat people with complex regional pain syndrome (CRPS). Objectives: To assess the efficacy of LASB for the…

AdultCausalgiamedicine.medical_specialtyMEDLINElocal anesthetic agentPlacebonerve block03 medical and health sciences0302 clinical medicine030202 anesthesiologymedicineHumanspainPharmacology (medical)Anesthetics LocalChildAdverse effectRandomized Controlled Trials as Topicbusiness.industrymedicine.diseaseReflex Sympathetic DystrophyClinical trialSystematic reviewComplex regional pain syndromeSympathetic BlockMeta-analysisAnesthesiaPhysical therapybusinessComplex Regional Pain Syndromes030217 neurology & neurosurgeryAutonomic Nerve BlockCochrane Database of Systematic Reviews
researchProduct

Central action of cinnarizine and flunarizine: A saccadic eye movement study

1994

The mechanism of action of flunarizine (FZ) and cinnarizine (CZ) on the CNS is not fully understood. Computer analysis of saccadic eye movements (SEM) provides a sensitive and objective method for evaluating drug effect on the function of specific brain structures. This study aimed to assess the effect of a single oral dose of FZ (20 mg) and CZ (150 mg) on CNS function by means of computer analysis of SEM. Ten healthy volunteers were studied according to a double-blind, cross-over, placebo-controlled design. Peak saccadic velocity (PSV), which is related to the function of a specific group of burst neurons located in the brain stem, was significantly reduced by FZ. No significant effect of …

AdultCentral Nervous SystemMaleCinnarizineCentral nervous systemAdministration OralCinnarizinePlacebosDouble-Blind MethodmedicineSaccadesHumansPharmacology (medical)FlunarizinePharmacologyCross-Over StudiesDose-Response Relationship Drugbusiness.industryEye movementCalcium Channel BlockersSaccadic maskingElectrophysiologymedicine.anatomical_structureMechanism of actionSaccadeNeurology (clinical)medicine.symptombusinessNeuroscienceFlunarizinemedicine.drug
researchProduct

Combination treatment with nefazodone and cognitive-behavioral therapy for relapse prevention in alcohol-dependent men: a randomized controlled study.

2004

Background This study evaluated the serotonergic antidepressant nefazodone versus placebo and specific cognitive-behavioral therapy (CBT) versus nondirective group counseling (GC) for relapse prevention in alcohol dependence in a large prospective, randomized, and placebo-controlled double-blind study at 3 German university centers. Method 242 male patients fulfilling at least 5 criteria for alcohol dependence according to DSM-IV and ICD-10 were eligible, after detoxification, for one of the following treatment combinations: nefazodone + CBT, nefazodone + GC, placebo + CBT, and placebo + GC. Either nefazodone or placebo was administered throughout the evaluation period of 15 months. Either …

AdultCounselingMalemedicine.medical_specialtymedicine.medical_treatmentRelapse preventionPlaceboPiperazineslaw.inventionGroup psychotherapyPlacebosRandomized controlled triallawInternal medicinemedicineSecondary PreventionHumansDiagnosis Computer-AssistedPsychiatryPsychiatric Status Rating ScalesCognitive Behavioral TherapyAlcohol dependenceTriazolesCombined Modality TherapyClinical trialCognitive behavioral therapyPsychiatry and Mental healthAlcoholismTreatment OutcomePsychologyNefazodonemedicine.drugThe Journal of clinical psychiatry
researchProduct

Efficacy of leukotriene receptor antagonist in chronic urticaria. A double-blind, placebo-controlled comparison of treatment with montelukast and cet…

2001

Background The cause and pathogenesis of chronic urticaria are still poorly understood. IgE-independent reactions, are common in adult patients with chronic urticaria, who have daily spontaneous occurrence of weals. H1-receptor antagonists (antihistamines) are the major class of therapeutic agents used in the management of urticaria and angioedema. Nevertheless, chronic urticaria is often difficult to treat and may not be controlled by antihistamines alone. It has been postulated that mediators other than histamine, such as kinins, prostaglandin and leukotrienes, may be responsible for some of the symptoms in urticaria which are not controlled by antihistamines. In this study, which was ran…

AdultCyclopropanesMalemedicine.medical_specialtyAdolescentUrticariaImmunologyAcetatesSulfidesPlaceboGastroenterologyDouble-Blind Methodimmune system diseasesInternal medicinemedicineImmunology and AllergyHumansskin and connective tissue diseasesAdverse effectMontelukastAgedLeukotrieneAngioedemaAspirinLeukotriene receptorbusiness.industryIncidenceMiddle Agedmedicine.diseaseCetirizineCetirizineFood intoleranceTreatment OutcomeItalyImmunologyChronic DiseaseHistamine H1 AntagonistsQuinolinesLeukotriene AntagonistsFemaleFood AdditivesSleep Stagesmedicine.symptombusinessFood Hypersensitivitymedicine.drugClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
researchProduct

Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for…

2004

BACKGROUND: H 1 -receptor antagonists are considered to be particularly effective in reducing pruritus, and they are therefore recommended as first-line treatment in patients with chronic idiopathic urticaria (CIU). Recently, antileukotriene receptors have been used in patients with CIU, either administered as monotherapy or combined with H 1 -receptor antagonists. OBJECTIVE: We compared the clinical efficacy of 5 mg of desloratadine administered once daily either as monotherapy or combined with a leukotriene antagonist, 10 mg of montelukast daily, and 10 mg of montelukast administered daily as monotherapy for the treatment of patients affected by CIU with placebo. METHODS: One hundred sixt…

AdultCyclopropanesMalemedicine.medical_specialtyHistamine H1 Antagonists Non-SedatingSettore MED/09 - Medicina InternaAdolescentUrticariamedicine.medical_treatmentImmunologyPlacebo-controlled studyRandomized placebo-controlled trial; desloratadine; montelukast; chronic idiopathic urticariaAcetatesSulfidesPlaceboGastroenterologylaw.inventionchemistry.chemical_compoundRandomized controlled trialDouble-Blind MethodlawInternal medicinemedicineImmunology and AllergyHumansMontelukastAgedDesloratadineLeukotriene E4Leukotriene receptorbusiness.industrydesloratadineRandomized placebo-controlled trialLoratadineMiddle AgedAntileukotrieneTreatment OutcomechemistryAnesthesiachronic idiopathic urticariaChronic DiseasemontelukastQuinolinesLeukotriene AntagonistsFemalebusinessmedicine.drug
researchProduct

Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two ra…

2020

Thyroid eye disease manifests inflammation and treatment-resistant proptosis and diplopia. Teprotumumab, an insulin-like growth factor-1 receptor inhibiting monoclonal antibody, was approved in the USA on Jan 21, 2020, on the basis of two randomised trials. In this analysis we evaluated the short-term and long-term aggregate response to teprotumumab from the two trials, focusing on proptosis and diplopia.We analysed integrated outcomes and follow-up data from two randomised, double-masked, placebo-controlled, multicentre, trials done at a total of 28 academic referral tertiary specialised centres offering joint thyroid eye clinics, or orbital clinics or practices, or both, in Europe and the…

AdultData AnalysisMalemedicine.medical_specialtyEndocrinology Diabetes and MetabolismEye diseasePopulation030209 endocrinology & metabolismAntibodies Monoclonal HumanizedPlaceboSeverity of Illness Indexlaw.inventionPlacebos03 medical and health sciences0302 clinical medicineEndocrinologyDouble-Blind MethodRandomized controlled triallawInternal medicineSeverity of illnessInternal MedicinemedicineHumans030212 general & internal medicineeducationAgedDiplopiaeducation.field_of_studybusiness.industryThyroidMiddle Agedmedicine.diseaseUnited Stateseye diseasesEuropeGraves OphthalmopathyTreatment Outcomemedicine.anatomical_structureFemalemedicine.symptombusinessOff TreatmentFollow-Up StudiesThe Lancet Diabetes & Endocrinology
researchProduct

Acute, subchronic and discontinuation effects of zopiclone on sleep EEG and nocturnal melatonin secretion

1996

Zopiclone is a new short half-life cyclopyrrolone hypnotic agent acting at the GABA-benzodiazepine receptor complex. In order to characterize its pharmacological profile, the effects of 7.5 mg zopiclone on nocturnal melatonin secretion were investigated under polysomnographic control in 11 healthy subjects following acute and subchronic administration as well as after abrupt discontinuation of the drug. No effect of zopiclone on the melatonin plasma levels could be observed. Regarding both total melatonin production and the temporal pattern of melatonin secretion during the night, there was no difference between placebo baseline condition, acute and subchronic administration, and discontinu…

AdultDrugReceptor complexmedicine.medical_specialtyTime Factorsmedicine.drug_classmedia_common.quotation_subjectPharmacologyPlaceboPiperazinesHypnoticMelatoninInternal medicinemedicineHumansHypnotics and SedativesPharmacology (medical)ChildBiological PsychiatryMelatoninmedia_commonPharmacologyZopicloneElectroencephalographyDiscontinuationPsychiatry and Mental healthEndocrinologyNeurologyPharmacodynamicsNeurology (clinical)SleepPsychologyAzabicyclo Compoundsmedicine.drugEuropean Neuropsychopharmacology
researchProduct

Caffeine Increases Strength and Power Performance in Resistance-trained Females During Early Follicular Phase

2020

The effects of 4 mg·kg−1caffeine ingestion on strength and power were investigated for the first time, in resistance-trained females during the early follicular phase utilizing a randomized, double-blind, placebo-controlled, crossover design. Fifteen females (29.8 ± 4.0 years, 63.8 ± 5.5 kg [mean ± SD]) ingested caffeine or placebo 60 minutes before completing a test battery separated by 72 hours. One-repetition maximum (1RM), repetitions to failure (RTF) at 60% of 1RM, was assessed in the squat and bench press. Maximal voluntary contraction torque (MVC) and rate of force development (RFD) were measured during isometric knee extensions, while utilizing interpolated twitch technique to measu…

AdultEarly follicular phaseWeight LiftingPhysical ExertionPhysical Therapy Sports Therapy and RehabilitationSquatStrength performancesIsometric exercisePerformance-Enhancing SubstancesPlyometric ExercisePlaceboMuscular activation levelsBench pressBeverageschemistry.chemical_compoundDouble-Blind MethodFemale athletesCaffeineIsometric ContractionIngestionMedicineHumansOrthopedics and Sports MedicineKneeMuscle StrengthCaffeine supplementationsCross-Over Studiesbusiness.industryResistance TrainingMyalgiaVDP::Medisinske Fag: 700::Idrettsmedisinske fag: 850Crossover studychemistryFollicular PhaseMuscular endurancesAnesthesiaFemalePerceptionPower performancesCaffeinebusiness
researchProduct

Once-daily tiotropium Respimat® 5 μg is an efficacious 24-h bronchodilator in adults with symptomatic asthma

2015

SummaryIntroductionOnce-daily tiotropium Respimat® 5 μg is an efficacious add-on therapy to inhaled corticosteroids (ICS) with or without long-acting β2-agonists in patients with symptomatic asthma. The objective of this study was to investigate whether the dosing regimen of tiotropium (once- versus twice-daily), delivered via the Respimat® SoftMist™ inhaler, affected 24-h bronchodilator efficacy and safety versus placebo Respimat® in patients with asthma who were symptomatic despite medium-dose ICS therapy.MethodsA randomised, double-blind, placebo-controlled, crossover study with 4-week treatment periods of tiotropium 5 μg (once-daily, evening) and 2.5 μg (twice-daily, morning and evening…

AdultEstoniaMalePulmonary and Respiratory MedicineVital capacityRespimatEveningAdolescentmedicine.drug_classPlaceboDouble-Blind MethodRisk FactorsAnticholinergic drugForced Expiratory VolumeGermanyBronchodilatorAdministration InhalationmedicineHumansDosingDosing regimenTiotropium BromideAgedCzech RepublicAsthmaLong-acting bronchodilatorCross-Over StudiesDose-Response Relationship Drugbusiness.industryTiotropiumInhalerMiddle Agedmedicine.diseaseLatviaAsthmaBronchodilator Agentsrespiratory tract diseasesTreatment OutcomeBronchodilator efficacyAustriaAnesthesiaFemalebusinessRespiratory Medicine
researchProduct

Tacrolimus Monotherapy Without Steroids After Liver Transplantation – A Prospective Randomized Double-Blinded Placebo-Controlled Trial

2007

Early steroid withdrawal after liver transplantation (LT) is desirable in order to reduce steroid side effects. Between February 2000 and August 2004, 110 patients after LT were included in this prospective, randomized, double-blind, placebo-controlled trial. Randomization was performed before LT. In all patients, tacrolimus was used without induction therapy. All patients received methylprednisolon for 14 days, thereafter a double-blinded medication containing either placebo (n = 56) or methylprednisolon (n = 54) for 6 months, which was completely stopped thereafter. End points were patient and graft survival, acute and chronic rejection, and incidence of steroid side effects during the fi…

AdultGraft RejectionMalemedicine.medical_specialtyTime FactorsRandomizationmedicine.drug_classmedicine.medical_treatmentPlacebo-controlled studyLiver transplantationPlaceboMethylprednisoloneGastroenterologyTacrolimuslaw.inventionPlacebosDouble-Blind MethodRandomized controlled trialAdrenal Cortex HormoneslawInternal medicinemedicineHumansImmunology and AllergyPharmacology (medical)Antibacterial agentTransplantationbusiness.industryMiddle AgedTacrolimusLiver TransplantationSurgeryCorticosteroidFemaleSafetybusinessImmunosuppressive AgentsFollow-Up StudiesAmerican Journal of Transplantation
researchProduct